TikoMed’s ILB® activates the body’s natural repair signals to restore glutamate homeostasis, amino acid metabolism and neurocognitive functions in a rat model of severe traumatic brain injury
- Wednesday, August 3, 2022, 4:05
- PR Newswire
- Add a comment
VIKEN, Sweden, Aug. 3, 2022 /PRNewswire/ — A new study with TikoMed’s lead drug candidate, ILB®, addressing underlying causes of neurodegeneration in acute and chronic diseases, was published in the International Journal of Molecular Sciences today. The data from the rodent model…
About the Author
admin has written 20655 stories on this site.